CYP450 3A4 / 3A5 Genotyping
Cytochrome P450 3A4/5 (CYP3A4/3A5) acts on approximately half of all drugs in clinical use. About 8% of Caucasians have a slow acting, intermediate metabolizer form of CYP3A4 (CYP3A4 *22). 
Prevalence of CYP3A5 variants differs widely by ethnic origin. Approximately 11-12% of Asian and African Americans have non-functional CYP3A5 alleles (CYP3A5 *6, *7). CYP3A4 and CYP3A5 are closely related and may process many of the same drugs. Substrates include opioid pain medications, statins, chemotherapeutic drugs, and combined oral contraceptives.
Genelex offers improved detection rates using a Cytochrome P450 3A4 mutation panel and a Cytochrome P450 3A5 DNA test. These tests each identify common clinically relevant alleles in their respective genes (CYP3A4: *1B,*22. CYP3A5: *3,*6,*7) in PCR-multiplex format. Analytical specificity and sensitivity for detection of these mutations are >99%.
Genelex offers improved detection rates using a Cytochrome P450 3A4 mutation panel and a Cytochrome P450 3A5 DNA test. These tests each identify one clinically-relevant single nucleotide variant in their respective genes in PCR-multiplex format. Analytical specificity and sensitivity for detection of these mutations are >99%.
Indication for CYP3A4/CYP3A5 Testing
For individuals with a personal or family history of adverse drug reactions to medications metabolized by CYP3A4/3A5.
CPT Codes: CYP3A4 and CYP3A5 Mutation DNA Analysis: 81230; 81231 (provided as guidance only).
Please call Client Services at 800-837-8362 to order testing supplies.
- Buccal Swabs: 4 sterile buccal swabs (preferred)
- Blood: 5-10cc whole blood lavender-top EDTA or yellow-top ACD-A tubes
- Turnaround Time: 10 business days, faster turnaround available for clinical trials